D R Webb1, F Zaccardi1, M J Davies1, S J Griffin2,3, N J Wareham2, R K Simmons2, G E Rutten4, A Sandbaek5, T Lauritzen5, K Borch-Johnsen6, K Khunti1. 1. Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK. 2. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK. 3. Primary Care Unit, Cambridge Institute of Public Health, Cambridge, UK. 4. Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, Netherlands. 5. School of Public Health, Section of General Practice, University of Aarhus, Aarhus, Denmark. 6. Holbaek Hospital, Holbaek, Denmark.
Abstract
BACKGROUND: It is unclear whether cardiovascular risk factor modification influences the development of renal disease in people with type 2 diabetes identified through screening. We determined predictors of albuminuria 5 years after a diagnosis of screen-detected diabetes within the ADDITION-Europe study, a pragmatic cardiovascular outcome trial of multifactorial cardiovascular risk management. METHODS: In 1826 participants with newly diagnosed, screen-detected diabetes without albuminuria, we explored associations between risk of new albuminuria (≥2.5 mg mmol-1 for males and ≥3.5 mg mmol-1 for females) and (1) baseline cardio-metabolic risk factors and (2) changes from baseline to 1 year in systolic blood pressure (ΔSBP) and glycated haemoglobin (ΔHbA1c ) using logistic regression. RESULTS: Albuminuria developed in 268 (15%) participants; baseline body mass index and active smoking were independently associated with new onset albuminuria in 5 years after detection of diabetes. In a model adjusted for age, gender, baseline HbA1c and blood pressure, a 1% decrease in HbA1c and 5-mm Hg decrease in SBP during the first year were independently associated with lower risks of albuminuria (odds ratio), 95% confidence interval: 0.76, 0.62 to 0.91 and 0.94, 0.88 to 1.01, respectively. Further adjustment did not materially change these estimates. There was no interaction between ΔSBP and ΔHbA1c in relation to albuminuria risk, suggesting likely additive effects on renal microvascular disease. CONCLUSIONS: Baseline measurements and changes in HbA1c and SBP a year after diagnosis of diabetes through screening independently associate with new onset albuminuria 4 years later. Established multifactorial treatment for diabetes applies to cases identified through screening.
BACKGROUND: It is unclear whether cardiovascular risk factor modification influences the development of renal disease in people with type 2 diabetes identified through screening. We determined predictors of albuminuria 5 years after a diagnosis of screen-detected diabetes within the ADDITION-Europe study, a pragmatic cardiovascular outcome trial of multifactorial cardiovascular risk management. METHODS: In 1826 participants with newly diagnosed, screen-detected diabetes without albuminuria, we explored associations between risk of new albuminuria (≥2.5 mg mmol-1 for males and ≥3.5 mg mmol-1 for females) and (1) baseline cardio-metabolic risk factors and (2) changes from baseline to 1 year in systolic blood pressure (ΔSBP) and glycated haemoglobin (ΔHbA1c ) using logistic regression. RESULTS: Albuminuria developed in 268 (15%) participants; baseline body mass index and active smoking were independently associated with new onset albuminuria in 5 years after detection of diabetes. In a model adjusted for age, gender, baseline HbA1c and blood pressure, a 1% decrease in HbA1c and 5-mm Hg decrease in SBP during the first year were independently associated with lower risks of albuminuria (odds ratio), 95% confidence interval: 0.76, 0.62 to 0.91 and 0.94, 0.88 to 1.01, respectively. Further adjustment did not materially change these estimates. There was no interaction between ΔSBP and ΔHbA1c in relation to albuminuria risk, suggesting likely additive effects on renal microvascular disease. CONCLUSIONS: Baseline measurements and changes in HbA1c and SBP a year after diagnosis of diabetes through screening independently associate with new onset albuminuria 4 years later. Established multifactorial treatment for diabetes applies to cases identified through screening.
Authors: M van den Donk; A Sandbaek; K Borch-Johnsen; T Lauritzen; R K Simmons; N J Wareham; S J Griffin; M J Davies; K Khunti; G E H M Rutten Journal: Diabet Med Date: 2011-11 Impact factor: 4.359
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: Sophia Zoungas; John Chalmers; Bruce Neal; Laurent Billot; Qiang Li; Yoichiro Hirakawa; Hisatomi Arima; Helen Monaghan; Rohina Joshi; Stephen Colagiuri; Mark E Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Liu Lisheng; Giuseppe Mancia; Michel Marre; David R Matthews; Carl E Mogensen; Vlado Perkovic; Neil Poulter; Anthony Rodgers; Bryan Williams; Stephen MacMahon; Anushka Patel; Mark Woodward Journal: N Engl J Med Date: 2014-09-19 Impact factor: 91.245
Authors: Simon J Griffin; Knut Borch-Johnsen; Melanie J Davies; Kamlesh Khunti; Guy E H M Rutten; Annelli Sandbæk; Stephen J Sharp; Rebecca K Simmons; Maureen van den Donk; Nicholas J Wareham; Torsten Lauritzen Journal: Lancet Date: 2011-06-24 Impact factor: 79.321